

# Acute Treatment of Migraine in Children aged 6-11: Real-World Analysis of Remote Electrical Neuromodulation (REN)


Pamela Rapiti<sup>1</sup>, Sukhpreet Singh<sup>2</sup>, Alicia McMaster<sup>3</sup>, Kiolan Naidoo<sup>3#</sup> Badal Suthar<sup>2</sup>, Alit Stark-Inbar<sup>4\*</sup>

1 Discipline of Paediatrics & Child Health, University of KwaZulu-Natal, Durban, South Africa; 2 Clinical Innovations, Dr.Reddy's Laboratories, Hyderabad, India; 3 Oncology & Horizon 2, Dr. Reddy's Laboratories, Johannesburg, South Africa;

4 Clinical Development and Research, Theranica Bio Electronics Ltd., Netanya, Israel; # Presenter\* Corresponding Author

## BACKGROUND

Migraine is a prevalent neurological disorder severely impacting children and adolescents, yet only one pharmacological treatment is approved for ages 6-12 years. Remote Electrical Neuromodulation (REN) is nonpharmacological, prescribed, wearable-device, FDA-cleared for acute and/or preventive treatment of migraine with or without aura in patients 12 years and older. This study evaluates REN's safety and efficacy in 6-11 years old.



## METHODS

Prospective acute treatment of migraine data was collected through the REN device (Nerivio®) smartphone application. Endpoints were device safety (primary); consistent treatment efficacy (headache pain, functional disability, associated migraine symptoms) and REN-medication combinations 2-hours post-treatment.





## REFERENCES

1. Abu-Arafeh I, Razak S, Sivaraman B, Graham C. Prevalence of headache and migraine in children and adolescents: a systematic review of population-based studies. *Dev Med Child Neurol*. 2010 Dec;52(12):1088–97. 2. Yang Y, Cao Y. Rising trends in the burden of migraine and tension-type headache among adolescents and young adults globally, 1990 to 2019. *The Journal of Headache and Pain*. 2023 Jul 27;24(1):94. 3. Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF, et al. Migraine prevalence, disease burden, and the need for preventive therapy. *Neurology*. 2007 Jan 30;68(5):343–9. 4. Abu-Arafeh I, Howells R. Primary headaches in children under the age of 7 years. *Curr Pain Headache Rep*. 2014 Mar;18(3):401. 5. Gelfand AA, Reider AC, Goadsby PJ. Cranial autonomic symptoms in pediatric migraine are the rule, not the exception. *Neurology*. 2013 Jul 30;81(5):431–6. 6. Hershey AD, Winner P, Kabbouche MA, Gladstein J, Yonker M, Lewis D, et al. Use of the ICHD-II Criteria in the Diagnosis of Pediatric Migraine. *Headache: The Journal of Head and Face Pain*. 2005;45(10):1288–97. 7. Szperka C. Headache in Children and Adolescents. *Continuum (Minneapolis, Minn)*. 2021 Jun 1;27(3):703–31. 8. Powers SW, Patton SR, Hommel KA, Hershey AD. Quality of life in childhood migraines: clinical impact and comparison to other chronic illnesses. *Pediatrics*. 2003 Jul;112(1 Pt 1):e1–5. 9. Heng K, Wirrell E. Sleep disturbance in children with migraine. *J Child Neurol*. 2006 Sep;21(9):761–6. 10. Stang PE, Osterhaus JT. Impact of Migraine in the United States: Data from the National Health Interview Survey. *Headache: The Journal of Head and Face Pain*. 1993;33(1):29–35. 11. O'Donnell DM, Agin A. Management of headaches in children and adolescents. *Current Problems in Pediatric and Adolescent Health Care*. 2021 Jul 1;51(7):101034. 12. Vos T, Abajobir AA, Abate KH, Abbafati C, Abbas KM, Abd-Alrah F, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. *The Lancet*. 2017;390(10100):1211–59. 13. Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi M, Abbasifard M, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. *The Lancet*. 2020 Oct 17;396(10258):1204–22. 14. Sillanpää M, Saarela MM. Long term outcome of childhood onset headache: A prospective community study. *Cephalalgia*. 2018 May;38(6):1159–66. 15. Furnham A, Cheng H. Childhood onset of migraine, gender, psychological distress and locus of control as predictors of migraine in adulthood. *Psychol Health Med*. 2023;28(8):2045–57. 16. Kroon Van Diest AM, Ernst MM, Slater S, Powers SW. Similarities and Differences Between Migraine in Children and Adults: Presentation, Disability, and Response to Treatment. *Curr Pain Headache Rep*. 2017 Oct 25;21(12):48. 17. Oskoui M, Pringsheim T, Holler-Magayan Y, Potrebic S, Billinghamhurst L, Gloss D, et al. Practice guideline update summary: Acute treatment of migraine in children and adolescents: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society. *Neurology*. 2019 Sep 10;93(11):487–99. 18. Gelfand AA, Goadsby PJ. Medication Overuse in Children and Adolescents. *Curr Pain Headache Rep*. 2014 Jul;18(7):428. 19. Johnson HF, Goadsby PJ, Gelfand AA. Predictors of Triptan Response in Pediatric Migraine. *Pediatr Neurol*. 2016 May;58:37–40. 20. Goadsby PJ, Sprenger T. Current practice and future directions in the prevention and acute management of migraine. *The Lancet Neurology*. 2010 Mar 1;9(3):285–98. 21. Diener HC, Limmroth V. Medication-overuse headache: a worldwide problem. *The Lancet Neurology*. 2004 Aug 1;3(8):475–83. 22. Bigal ME, Lipton RB. Overuse of acute migraine medications and migraine chronification. *Curr Pain Headache Rep*. 2009 Aug;13(4):301–7. 23. Nir RR, Yarnitsky D. Conditioned pain modulation. Current opinion in supportive and palliative care. 2015;9(2):131–7. 24. Babaei M, Rappoport AM. Device profile of Nerivio for the acute and preventive treatment of episodic or chronic migraine in patients 12 years and older. *Expert Rev Med Devices*. 2023 Jun;20(6):433–47. 25. Fryar CD, Gu Q, Ogden CL, Flegal KM. Anthropometric Reference Data for Children and Adults: United States, 2011–2014. *Vital Health Stat 3 Anal Stud*. 2016 Aug;(39):1–46. 26. Yarnitsky D, Dodick DW, Grosberg BM, Burstein R, Ironi A, Harris D, et al. Remote Electrical Neuromodulation (REN) Relieves Acute Migraine: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial. *Headache: The Journal of Head and Face Pain*. 2019;59(8):1240–52. 27. Yarnitsky D, Volokh L, Ironi A, Weller B, Shor M, Shifrin A, et al. Nonpainful remote electrical stimulation alleviates episodic migraine pain. *Neurology*. 2017;88(13):1250–5. 28. Tepper SJ, Rabany L, Cowan RP, Smith TR, Grosberg BM, Torphy BD, et al. Remote electrical neuromodulation for migraine prevention: A double-blind, randomized, placebo-controlled clinical trial. *Headache*. 2023 Mar;63(3):377–89. 29. Hershey AD, Lin T, Gruper Y, Harris D, Ironi A, Berk T, et al. Remote electrical neuromodulation for acute treatment of migraine in adolescents. *Headache*. 2021 Feb;61(2):310–7. 30. Eshparham A, Stark-Inbar A, Jekel L, Tamir S, Rabany L, Ironi A, et al. Acute Treatment of Migraine in Adolescents: Real-World Analysis of Remote Electrical Neuromodulation (REN). *Pediatric Neurology*. 2023 May 1;142:51–5. 31. Monteith TS, Stark-Inbar A, Shmueli S, Harris D, Garas S, Ironi A, et al. Remote electrical neuromodulation (REN) wearable device for adolescents with migraine: a real-world study of high-frequency abortive treatment suggests preventive effects. *Front Pain Res (Lausanne)*. 2023;4:1247313. 32. Hershey AD, Irwin S, Rabany L, Gruper Y, Ironi A, Harris D, et al. Comparison of Remote Electrical Neuromodulation and Standard-Care Medications for Acute Treatment of Migraine in Adolescents: A Post Hoc Analysis. *Pain Med*. 2022 Apr 8;23(4):815–20. 33. Nierenburg H, Stark-Inbar A. Nerivio® remote electrical neuromodulation for acute treatment of chronic migraine. *Pain Manag*. 2022 Apr;12(3):267–81. 34. Allani J, Rabany L, Tamir S, Ironi A, Starling A. Real-World Analysis of Remote Electrical Neuromodulation (REN) for the Acute Treatment of Migraine. *Front Pain Res (Lausanne)*. 2021;2:753736. 35. Tepper SJ, Lin T, Montal T, Ironi A, Dougherty C. Real-world Experience with Remote Electrical Neuromodulation in the Acute Treatment of Migraine. *Pain Med*. 2020 Dec 25;21(12):3522–9. 36. Synowiec A, Stark-Inbar A, Weinstein M, Ironi A, Mauskop A. One-Year Consistent Safety, Utilization, and Efficacy Assessment of Remote Electrical Neuromodulation (REN) for Migraine Treatment. *Adv Ther*. 2024 Jan;41(1):170–81. 37. Ahonen K, Hämmäläinen ML, Eerola M, Hoppu K. A randomized trial of rizatriptan in migraine attacks in children. *Neurology*. 2006 Oct 10;67(7):1135–40. 38. Ho TW, Pearlman E, Lewis D, Hämmäläinen M, Connor K, Michelson D, et al. Efficacy and tolerability of rizatriptan in pediatric migraineurs: results from a randomized, double-blind, placebo-controlled trial using a novel adaptive enrichment design. *Cephalalgia*. 2012 Jul;32(10):750–65. 39. Kacperski J, Hershey AD. Newly Approved Agents for the Treatment and Prevention of Pediatric Migraine. *CNS Drugs*. 2016 Sep;30(9):837–44. 40. Lautenbacher S, Kunz M, Strafe P, Nielsen J, Arendt-Nielsen L. Age effects on pain thresholds, temporal summation and spatial summation of heat and pressure pain. *Pain*. 2005 Jun;115(3):410–8. 41. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. *Headache*. 2001 Aug;41(7):646–57. 42. Powers SW, Coffey CS, Chamberlin LA, Ecklund DJ, Klingner EA, Yankey JW, et al. Trial of Amitriptyline, Topiramate, and Placebo for Pediatric Migraine. *N Engl J Med*. 2017 Jan 12;376(2):115–24. 43. Locher C, Kossovsky I, Koechlin H, Lam TL, Barthel J, Berde CB, et al. Efficacy, Safety, and Acceptability of Pharmacologic Treatments for Pediatric Migraine Prophylaxis: A Systematic Review and Network Meta-analysis. *JAMA Pediatr*. 2020 Apr 1;174(4):341–9. 44. Orenius T, LicPsych null, Sällä H, Mikola K, Ristolainen L. Fear of injections and Needle Phobia Among Children and Adolescents: An Overview of Psychological, Behavioral, and Contextual Factors. *SAGE Open Nurs*. 2018;4:2377960818759442. 45. Taddio A, Ipp M, Thivakaran S, Jamal A, Parikh C, Smart S, et al. Survey of the prevalence of immunization non-compliance due to needle fears in children and adults. *Vaccine*. 2012 Jul 6;30(32):4807–12.

## RESULTS

Children (n=293), median age 11 (IQR=9-11), 73.7% girls, conducted 5,493 REN treatments.

**No adverse events and no device-related adverse events were reported.** An additional analysis assessed the number of device-related customer support inquiries conducted by this patient cohort (usually through their parents), showing an average of 0.072 inquiries per child, which is similar to the inquiry rate of the entire population of REN users, in all ages (0.067)



REN was used standalone, with over-the-counter medications, with prescribed headache medications in 45.4%, 34.4%, 20.9% of treatments, respectively.

## CONCLUSIONS

REN may serve as a safe and efficacious acute treatment of migraine for children. Providers and families seeking a safe, effective, pill- and needle-free treatment option for children suffering from migraine may consider REN.